Your browser doesn't support javascript.
loading
Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results.
Usmani, Saad Z; Mateos, Maria-Victoria; Hungria, Vania; Iida, Shinsuke; Bahlis, Nizar J; Nahi, Hareth; Magen, Hila; Cavo, Michele; Hulin, Cyrille; White, Darrell; De Stefano, Valerio; Fastenau, John; Slavcev, Mary; Heuck, Christoph; Qin, Xiang; Pei, Huiling; Masterson, Tara; Lantz, Kristen; Gries, Katharine S.
Afiliación
  • Usmani SZ; Plasma Cell Disorders Division, Clinical Research for Hematologic Malignancies, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC, USA. saad.usmani@atriumhealth.org.
  • Mateos MV; University Hospital of Salamanca/IBSAL, Salamanca, Spain.
  • Hungria V; Clinica São Germano, São Paulo, Brazil.
  • Iida S; Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, Nagoya, Japan.
  • Bahlis NJ; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada.
  • Nahi H; Division of Hematology, Department of Medicine, Karolinska Institute, Karolinska University Hospital at Huddinge, Stockholm, Sweden.
  • Magen H; Department of Hematology, Chaim Sheba Medical Center, Ramat-Gan, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Cavo M; Department of Experimental, Diagnostic and Specialty Medicine, "Seràgnoli" Institute of Hematology, University of Bologna, Bologna, Italy.
  • Hulin C; Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France.
  • White D; Dalhousie University and QEII Health Sciences Centre, Halifax, NS, Canada.
  • De Stefano V; Institute of Hematology, Catholic University, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy.
  • Fastenau J; Janssen Global Services, LLC, Raritan, NJ, USA.
  • Slavcev M; Janssen Global Services, LLC, Raritan, NJ, USA.
  • Heuck C; Janssen Research & Development, LLC, Spring House, PA, USA.
  • Qin X; Janssen Research & Development, LLC, Spring House, PA, USA.
  • Pei H; Janssen Research & Development, LLC, Spring House, PA, USA.
  • Masterson T; Janssen Research & Development, LLC, Spring House, PA, USA.
  • Lantz K; Janssen Research & Development, LLC, Spring House, PA, USA.
  • Gries KS; Janssen Global Services, LLC, Raritan, NJ, USA.
J Cancer Res Clin Oncol ; 147(2): 619-631, 2021 Feb.
Article en En | MEDLINE | ID: mdl-32852632
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales / Mieloma Múltiple Tipo de estudio: Clinical_trials / Prognostic_studies Aspecto: Patient_preference Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Cancer Res Clin Oncol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales / Mieloma Múltiple Tipo de estudio: Clinical_trials / Prognostic_studies Aspecto: Patient_preference Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Cancer Res Clin Oncol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Alemania